[Effect of hyperoxic inhalations for athletes of different sports, including those who had COVID-19, when training in the middle altitude].

Objective: To identify hyperoxic inhalations on the functional state of the cardiorespiratory system of athletes of different sports, who have previously had COVID-19, when training in the middle altitude.

Material And Methods: The study included 64 elite athletes during the preparatory period. The studies were conducted in Kislovodsk in the middle altitude (1240 meters) on the Maloe Sedlo mountain, in the conditions of training camps.

[Effects of the beta-stimulating training in recovery of adaptive reserves in athletes of different sports].

Unlabelled: Application of the beta rhythm neurofeedback is mainly dealt with when considering issues related to improving attention for clinical or preventive purposes. Cognitive and autonomic interactions formed with the help of biofeedback training, changing the function of autonomic and visceral systems, qualitatively improve the efficiency of any activity, including athletic activity, the nature of which is predetermined by the type of sports.

Objective: To identify effects of the beta-stimulating training in recovery of adaptive reserves in athletes of different sports.

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.

Background: Many patients with chronic spontaneous urticaria (CSU) do not achieve complete control of their symptoms with current available treatments. In a dose-finding phase 2b study, ligelizumab improved urticaria symptoms in patients with H1-antihistamine (H1-AH) refractory CSU. Here, we report the efficacy and safety outcomes from two ligelizumab phase 3 studies.

Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study.

Introduction: Data on burden and treatment outcomes of chronic spontaneous urticaria (CSU) in Russia are limited. Poor adherence to recommended treatments can lead to suboptimal management of CSU patients.

Aim: To understand disease burden, treatment algorithms, and outcomes of CSU in the Russian cohort of the AWARE study.

Comparison of biosimilar Tigerase and Pulmozyme in long-term symptomatic therapy of patients with cystic fibrosis and severe pulmonary impairment (subgroup analysis of a Phase III randomized open-label clinical trial (NCT04468100)).

Background: Patients with cystic fibrosis (CF) need costly medical care and adequate therapy with expensive medicinal products. Tigerase® is the first biosimilar of dornase alfa, developed by the lead Russian biotechnology company GENERIUM. The aim of the manuscript to present post hoc sub-analysis of patients' data with cystic fibrosis and severe pulmonary impairment of a larger comparative study (phase III open label, prospective, multi-centre, randomized study (NCT04468100)) of a generic version of recombinant human DNase Tigerase® to the only comparable drug, Pulmozyme®.